The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1673
April 3, 2023
View Complete Issue         Table of Contents 2019 
Pegcetacoplan (Syfovre) for Geographic Atrophy in Age-Related Macular Degeneration
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Pegcetacoplan (Syfovre) for Geographic Atrophy in Age-Related Macular Degeneration
April 3, 2023 (Issue: 1673)
The FDA has approved the complement C3 inhibitor pegcetacoplan (Syfovre – Apellis) for treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Given as a series of monthly or every-other-month (EOM)...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Pegcetacoplan (Syfovre) for Geographic Atrophy in Age-Related Macular Degeneration
Article code: 1673a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.